全文获取类型
收费全文 | 3418190篇 |
免费 | 279992篇 |
国内免费 | 23059篇 |
专业分类
耳鼻咽喉 | 47182篇 |
儿科学 | 103545篇 |
妇产科学 | 90629篇 |
基础医学 | 470355篇 |
口腔科学 | 95612篇 |
临床医学 | 321809篇 |
内科学 | 667852篇 |
皮肤病学 | 72029篇 |
神经病学 | 281082篇 |
特种医学 | 136509篇 |
外国民族医学 | 1206篇 |
外科学 | 512201篇 |
综合类 | 109712篇 |
现状与发展 | 51篇 |
一般理论 | 1336篇 |
预防医学 | 275812篇 |
眼科学 | 79662篇 |
药学 | 255369篇 |
173篇 | |
中国医学 | 16412篇 |
肿瘤学 | 182703篇 |
出版年
2021年 | 32689篇 |
2019年 | 30137篇 |
2018年 | 40170篇 |
2017年 | 31946篇 |
2016年 | 35251篇 |
2015年 | 42179篇 |
2014年 | 58497篇 |
2013年 | 81838篇 |
2012年 | 108115篇 |
2011年 | 115755篇 |
2010年 | 70040篇 |
2009年 | 65616篇 |
2008年 | 104039篇 |
2007年 | 110163篇 |
2006年 | 110915篇 |
2005年 | 108610篇 |
2004年 | 101007篇 |
2003年 | 97228篇 |
2002年 | 93910篇 |
2001年 | 151232篇 |
2000年 | 156512篇 |
1999年 | 133105篇 |
1998年 | 41813篇 |
1997年 | 38158篇 |
1996年 | 37665篇 |
1995年 | 36970篇 |
1994年 | 34468篇 |
1993年 | 31733篇 |
1992年 | 106395篇 |
1991年 | 102993篇 |
1990年 | 99203篇 |
1989年 | 94924篇 |
1988年 | 88258篇 |
1987年 | 86988篇 |
1986年 | 82201篇 |
1985年 | 78884篇 |
1984年 | 60057篇 |
1983年 | 51157篇 |
1982年 | 31628篇 |
1979年 | 55831篇 |
1978年 | 39896篇 |
1977年 | 33586篇 |
1976年 | 31391篇 |
1975年 | 32943篇 |
1974年 | 40157篇 |
1973年 | 38242篇 |
1972年 | 35751篇 |
1971年 | 33131篇 |
1970年 | 30958篇 |
1969年 | 28809篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
11.
宫腔积液指宫腔内液体积存(积水、积血或积脓),是绝经后女性常见体征之一,常于超声检查时发现。持续宫腔积液患者,需宫腔镜检查寻找病因。本文报道1例以宫腔积液为首发症状,经宫腔镜检查确诊为胃型宫颈腺癌的患者。通过病例回顾并文献复习,以期为更多绝经后宫腔积液及宫颈病变的诊断提供参考,避免漏诊及误诊。1病例资料患者67岁,女,主因"绝经18年,不规则阴道出血2月"于2020年5月就诊于首都医科大学附属北京妇产医院妇科微创中心。 相似文献
12.
13.
Journal of Behavioral Medicine - Evidence supports the use of graphic warnings to educate the public about the health harms of smoking and suggests warnings eliciting negative emotional responses... 相似文献
14.
15.
16.
Qian Zhang Larry D. Mesner Gina M. Calabrese Naomi Dirckx Zhu Li Angela Verardo Qian Yang Robert J. Tower Marie-Claude Faugere Charles R. Farber Thomas L. Clemens 《The Journal of clinical investigation》2021,131(7)
Bone mineral density (BMD) is a highly heritable predictor of osteoporotic fracture. GWAS have identified hundreds of loci influencing BMD, but few have been functionally analyzed. In this study, we show that SNPs within a BMD locus on chromosome 14q32.32 alter splicing and expression of PAR-1a/microtubule affinity regulating kinase 3 (MARK3), a conserved serine/threonine kinase known to regulate bioenergetics, cell division, and polarity. Mice lacking Mark3 either globally or selectively in osteoblasts have increased bone mass at maturity. RNA profiling from Mark3-deficient osteoblasts suggested changes in the expression of components of the Notch signaling pathway. Mark3-deficient osteoblasts exhibited greater matrix mineralization compared with controls that was accompanied by reduced Jag1/Hes1 expression and diminished downstream JNK signaling. Overexpression of Jag1 in Mark3-deficient osteoblasts both in vitro and in vivo normalized mineralization capacity and bone mass, respectively. Together, these findings reveal a mechanism whereby genetically regulated alterations in Mark3 expression perturb cell signaling in osteoblasts to influence bone mass. 相似文献
17.
18.
19.
Melanie A. Krook Julie W. Reeser Gabrielle Ernst Hannah Barker Max Wilberding Gary Li Hui-Zi Chen Sameek Roychowdhury 《British journal of cancer》2021,124(5):880
Fibroblast growth factor receptors (FGFRs) are aberrantly activated through single-nucleotide variants, gene fusions and copy number amplifications in 5–10% of all human cancers, although this frequency increases to 10–30% in urothelial carcinoma and intrahepatic cholangiocarcinoma. We begin this review by highlighting the diversity of FGFR genomic alterations identified in human cancers and the current challenges associated with the development of clinical-grade molecular diagnostic tests to accurately detect these alterations in the tissue and blood of patients. The past decade has seen significant advancements in the development of FGFR-targeted therapies, which include selective, non-selective and covalent small-molecule inhibitors, as well as monoclonal antibodies against the receptors. We describe the expanding landscape of anti-FGFR therapies that are being assessed in early phase and randomised controlled clinical trials, such as erdafitinib and pemigatinib, which are approved by the Food and Drug Administration for the treatment of FGFR3-mutated urothelial carcinoma and FGFR2-fusion cholangiocarcinoma, respectively. However, despite initial sensitivity to FGFR inhibition, acquired drug resistance leading to cancer progression develops in most patients. This phenomenon underscores the need to clearly delineate tumour-intrinsic and tumour-extrinsic mechanisms of resistance to facilitate the development of second-generation FGFR inhibitors and novel treatment strategies beyond progression on targeted therapy.Subject terms: Cancer, Cancer 相似文献
20.
Her-Shyong Shiah Nai-Jung Chiang Chia-Chi Lin Chia-Jui Yen Hui-Jen Tsai Shang-Yin Wu Wu-Chou Su Kwang-Yu Chang Ching-Chiung Wang Jang-Yang Chang Li-Tzong Chen 《The oncologist》2021,26(4):e567-e579
Lessons Learned
- SCB01A is a novel microtubule inhibitor with vascular disrupting activity.
- This first‐in‐human study demonstrated SCB01A safety, pharmacokinetics, and preliminary antitumor activity.
- SCB01A is safe and well tolerated in patients with advanced solid malignancies with manageable neurotoxicity.